Barclays
SPHS

Barclays’s Sophiris Bio, Inc. SPHS Stock Holding History

Barclays’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,353
Closed -$1K – 7233
2019
Q3 		$1K Buy
+1,353
New +$1.2K ﹤0.01% 6658
2018
Q4 		– Sell
-2,600
Closed -$7K – 7811
2018
Q3 		$7K Sell
2,600
-10,800
-81% -$30.7K ﹤0.01% 6742
2018
Q2 		$38K Buy
13,400
+13,399
+1,339,900% +$39.8K ﹤0.01% 5821
2018
Q1 		$0 Buy
+1
New +$2 ﹤0.01% 7656
2014
Q4 		– Sell
-125
Closed – – 8029
2014
Q3 		$0 Buy
+125
New +$352 ﹤0.01% 8108

Other funds holding SPHS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Barclays's SPHS Position: Q4 2019 in Review

Barclays sold out of Sophiris Bio, Inc. (SPHS) in Q4 2019, closing a stake of 1,353 shares — an estimated $1K sold.

Barclays first reported a position in SPHS in Q3 2014 and held it in 5 quarters. The position peaked at $38K in Q2 2018. 27 funds tracked by Wall St. Rank hold SPHS as of Q4 2019.

  • Barclays reported no remaining Sophiris Bio, Inc. position as of Q4 2019 after selling out during the quarter.
  • Barclays sold 1,353 Sophiris Bio, Inc. shares in Q4 2019, an estimated $1K.
  • Barclays first reported a position in Sophiris Bio, Inc. in Q3 2014 and held it in 5 quarters.
  • Barclays's Sophiris Bio, Inc. position peaked at $38K in Q2 2018.
  • 27 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.